✦ LIBER ✦

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of lnterleukin-2 injected periiymphatically

✍ Scribed by Giorgio Cortesina; Antonella de Stefani; Mirella Giovarelli; Maria Grazia Barioglio; Giovanni P. Cavallo; Cristina Jemma; Guido Forni

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 388 KB
Volume: 62
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19881215)62:12<2482::aid-cncr2820621205>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of the neck in patients with s

Treatment of the neck in patients with squamous cell carcinoma of the head and neck

✍ Richard H. Jesse; Gilbert H. Fletcher 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB 👁 2 views

Sequential methotrexate–5-fluorouracil t

Sequential methotrexate–5-fluorouracil treatment of squamous cell carcinoma of the head and neck

✍ Ulrik Ringborg; GÖSta Ewert; Jan Kinnman; Per-Gotthard Lundqvist; Hans Strander 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate-5-fluorouracil followed by leucovorin rescue. The frequency of objective tumor regression obtained was 64% (complete response + partial response) with 19% complete regression. In 20 not pr

Immunoglobulin allotypes in patients wit

Immunoglobulin allotypes in patients with squamous cell carcinoma of the head and neck

✍ Theodorus Ockhuizen; Janardan P. Pandey; Robert W. Veltri; Myron Arlen; H. Hugh 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB 👁 2 views

Gm, A2m, and Km allotypic markers were examined in 40 Caucasian patients with squamous cell carcinomas of the head and neck. Serum IgA levels, the A2m(l) allotypic marker, and antibodies against IgAl, A2m(l), and A2m(2) were measured quantitatively. The frequency of Km(1) was found to be significant

Vinblastine, bleomycin and cisplatin for

Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck

✍ David J. Perry; Martin D. Weltz; Archie W. Brown Jr; Robert L. Henderson; Willia 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a

Cisplatin and 5-fluorouracil chemotherap

Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck

✍ Richard J. Mercier; G. David Neal; Douglas E. Mattox; George A. Gates; Thomas C. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB 👁 2 views

Paclitaxel, cisplatin, and 5-fluorouraci

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi